Dr Robert Dean speaks to ecancer about the initial report from the ECOG-ACRIN EA4151 phase 3 randomised trial.

The ECOG-ACRIN EA4151 study assesses the effectiveness of cell transplantation (auto-HCT) for mantle cell lymphoma patients in the first remission.

It involves four groups treated with rituximab-based regimens and tests for minimal residual disease.

Findings show no significant survival difference between transplant and non-transplant patients, especially those with negative minimal residual disease.

The study suggests a shift in treatment recommendations away from routine autologous cell transplantation.